Research Topics
| Gary T KinasewitzSummaryAffiliation: University of Oklahoma Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shockGary T Kinasewitz
University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Crit Care Med 36:1999-2007. 2008..To assess the safety and efficacy of the hemoglobin-based nitric oxide scavenger, pyridoxalated hemoglobin polyoxyethylene (PHP), in patients with distributive shock...- Hepatic hydrothoraxGary T Kinasewitz
Department of Medicine, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, USA
Curr Opin Pulm Med 9:261-5. 2003.... - Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]Gary T Kinasewitz
Department of Medicine, Physiology and Biophysics, University of Oklahoma Health Science Center, and Cardiovascular Biology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
Crit Care 8:R82-90. 2004..Coagulopathy and inflammation were universal host responses to infection in patients with severe sepsis, which were similar across causative micro-organism groups... - Troponin-I as a prognosticator of mortality in severe sepsis patientsJijo John
University of Oklahoma Health Sciences Center, Pulmonary Critical Care Medicine, Oklahoma City, OK 73104, USA
J Crit Care 25:270-5. 2010.... - Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apneaTarek A Dernaika
University of Oklahoma Health Sciences Center, Pulmonary and Critical Care Medicine, 920 Stanton L Young Blvd, WP 1310, Oklahoma City, OK 73104, USA
J Clin Sleep Med 5:103-7. 2009..To examine the long-term effects of continuous positive airway pressure (CPAP) therapy on blood pressure (BP) in patients with obstructive sleep apnea and resistant hypertension... - Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary diseaseTarek A Dernaika
University of Oklahoma Health Sciences Center, Pulmonary and Critical Care Medicine, Oklahoma City, OK 73104, USA
Respiration 79:377-82. 2010..Inhaled iloprost has the potential to act preferentially in ventilated regions of the lung, thereby reducing pulmonary hypertension (PH) while alveolar ventilation is still maintained... - The use of statins and lung function in current and former smokersJean I Keddissi
Pulmonary and Critical Care Medicine, the Oklahoma City VA Medical Center, Oklahoma City, OK, USA
Chest 132:1764-71. 2007..We assessed their ability to preserve lung function in current and former smokers... - The significance and outcome of continuous positive airway pressure-related central sleep apnea during split-night sleep studiesTarek Dernaika
University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Chest 132:81-7. 2007.... - Activated protein C improves survival in severe sepsis patients with elevated troponinJijo John
Pulmonary Critical Care Medicine, University of Oklahoma Health Sciences Center, 920 Stanton L Young Boulevard, Oklahoma City, OK 73104, USA
Intensive Care Med 33:2122-8. 2007..The elevated troponin in this situation is thought to be secondary to microthrombi. We hypothesized that recombinant human activated protein C (APC) treatment would improve outcomes in severe sepsis patients who have elevated troponin... - Prognostic value of a simple evolving disseminated intravascular coagulation score in patients with severe sepsisGary T Kinasewitz
Pulmonary and Critical Care Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Crit Care Med 33:2214-21. 2005..It can be easily calculated at the bedside and provides useful prognostic information for the patient with severe sepsis... - The diagnosis and management of disseminated intravascular coagulationFletcher B Taylor
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA
Curr Hematol Rep 1:34-40. 2002..The second part of this review covers the recent experience investigators have had in diagnosing and following the response of patients to treatment with biomarkers... - Reduced neutrophil CD10 expression in nonhuman primates and humans after in vivo challenge with E. coli or lipopolysaccharideToshihiro Kaneko
Free Radical Biology and Aging Research, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
Shock 20:130-7. 2003..This decrease appears to be unique to CD10 and may contribute to a reduced regulation of bioactive peptides released in response to inflammatory challenge... - Exudative effusions in congestive heart failureAlain A Eid
Departments of Pulmonary and Critical Care Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Chest 122:1518-23. 2002..We sought to determine the incidence and clinical significance of such exudative effusions... - Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS studyPierre-Francois Laterre
Head of Intensive Care Unit, Cliniques Universitaires Saint-Luc Service des Urgences et des Soins Intensifs, UCL, Brussels, Belgium
Crit Care Med 33:952-61. 2005..In patients with severe sepsis resulting from CAP, a readily identifiable disease, DrotAA, improved survival compared with placebo... - The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and resultsJean Francois Dhainaut
Department of Intensive Care, Cochin Hospital, Cochin Institute, Cochin Port Royal Medical School, Paris V University, France
Crit Care Med 31:2291-301. 2003..The objective of this study was to perform a blinded, critical, integrated review of data from the 1,690 severe sepsis patients from 164 medical centers enrolled in the PROWESS trial using a Clinical Evaluation Committee... - Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trialAlain Eid
Division of Pulmonary and Critical Care, CO Springs Memorial Hospital, CO Springs, Colorado, USA
Anesth Analg 107:1633-8. 2008..No data have been reported on the effects of AT therapy administered early in severe sepsis when microcirculation is disturbed but irreversible organ damage has not yet developed... - Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)Steven M Opal
Brown University School of Medicine, Providence, RI, USA
Clin Infect Dis 37:50-8. 2003..Results demonstrate that DrotAA, administered as an adjunct to standard anti-infective therapy, can improve the rate of survival for patients who develop severe sepsis regardless of causative microorganism... - Risk-benefit analysis for drotrecogin alfa (activated)Roland M H Schein
Division of Pulmonary and Critical Care Medicine, University of Miami School of Medicine, Critical Care Medicine III, 11300 Northeast Second Avenue, Miami Shore, FL 33125, USA
Am J Surg 184:S25-38. 2002..We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis...